Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Shattuck Labs Inc.
Headquarters: Austin, TX, United States of America
Website: http://www.shattucklabs.com
Year Founded: 2016
Status: Public
Industry Sector: HealthTechnology
CEO: Taylor H. Schreiber, MD, PhD
Number Of Employees: 44
Enterprise Value: $-8,163,469
PE Ratio: -0.55
Exchange/Ticker 1: NASDAQ:STTK
Exchange/Ticker 2: N/A
Latest Market Cap: $38,942,000
BioCentury | Oct 19, 2024
Finance
Biotech restructurings show signs of slowing
Temporary respite or reflection of a stabilizing sector?
BioCentury | Oct 1, 2024
Product Development
BCMA CAR Ts diverge in early lines, as Carvykti dominates market
In BioCentury’s latest Clinical Report, AbbVie hits in Parkinson’s, plus data from Shattuck, Merck and Celldex
BioCentury | Feb 21, 2024
Deals
Deal report: Astellas taps Kelonia for CAR Ts, Aurinia fails to find buyer, and more
Plus: Xoma-Kinnate, Almirall-Novo, Intellia-ReCode, Roche-Repare and more
BioCentury | Dec 14, 2023
Deals
Dec. 13 Quick Takes: Vertex heads off patent issues with Editas deal
Plus: Pfizer loses $11B in value after 2024 guidance and updates from J&J, Shattuck Labs, Vir, CARsgen, Freya and EvolveImmune
BioCentury | Jun 15, 2023
Data Byte
Status of the CD47/SIRPA clinical pipeline
The list of clinical candidates grows as biopharma steps up to overcome hematologic toxicities
BioCentury | Dec 22, 2021
Product Development
PD-1’s new narrative – a bonanza of innovation
Half the field is stuck in first gear, but a wealth of bispecifics, novel technologies are bringing new energy
BioCentury | Nov 24, 2021
Discovery & Translation
New mechanisms and modalities emerge for TIGIT
2021 ASH and SITC abstracts are low on data, high on innovation
BioCentury | Aug 23, 2021
Deals
Pfizer sees potential best-in-class CD47s in $2.3B Trillium takeout
In high-premium deal, Pfizer gains fusion proteins for blood cancers
BioCentury | Jun 3, 2021
Management Tracks
Gilde builds public markets expertise with Muijrers hire; plus Nanobiotix, Shattuck, Ichnos, Generate, Alpine and more
Joep Muijrers has joined Gilde Healthcare to lead the Dutch firm’s venture and growth capital fund. Muijrers is a veteran of PureTech Health plc (LSE:PRTC; NASDAQ:PRTC), where he served as
Items per page:
1 - 10 of 19